Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3

Conditions

Prostatic Neoplasms 52Brain Neoplasms 50Carcinoma, Non-Small-Cell Lung 48Neoplasm Metastasis 29Lung Neoplasms 29Breast Neoplasms 23Pancreatic Neoplasms 16Melanoma 15Carcinoma, Renal Cell 14Carcinoma, Hepatocellular 13Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Colorectal Neoplasms 7Kidney Neoplasms 5Liver Neoplasms 4Glioblastoma 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Spinal Cord Neoplasms 3Sarcoma 3Prostate Cancer Metastatic 3NSCLC 3Meningioma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Transitional Cell 3Adenocarcinoma 3

Interventions

Magnetic Resonance Spectroscopy 7lutetium Lu 177 dotatate 6Specimen Handling 5Bevacizumab 4gallium Ga 68 dotatate 3abemaciclib 3Radiosurgery 3Proton Therapy 3Nivolumab 3pembrolizumab 2Surveys and Questionnaires 2Sunitinib 2Protons 2Observation 2ONC206 2Ipilimumab 2Hydroxyurea 2Ga(III)-DOTATOC 2Everolimus 2Elasticity Imaging Techniques 2CTLA-4 Antigen 2ribociclib 1regorafenib 1olaparib 1neratinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1capivasertib 1cabozantinib 1brigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Meningioma × Radiosurgery × 1 year × Clear all
NCT03604978 2026-05-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
38 enrolled
CNS

Meningioma

NCT06466720 2026-05-04

CoDeB-Rad

University of Nottingham

Active not recruiting
80 enrolled
CNS

Brain Neoplasms, Meningioma, Cognitive Dysfunction

NCT04659811 2026-04-15

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

University of California, San Francisco

Phase 2 Active not recruiting
35 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡